Last edition
News about "Remibrutinib"
Novartis Remibrutinib Reduces Relapse Rates in Phase 3 RMS Trials
Novartis’ remibrutinib significantly reduces annualised relapse rates versus teriflunomide in phase 3 RMS trials, with a favorable safety profile and no liver safety signal.
Remibrutinib | 02/09/2026 | By News Bureau
Novartis' Rhapsido Gains UK Approval as First Oral BTK Inhibitor for Chronic Spontaneous Urticaria
Novartis has secured MHRA marketing authorisation for Rhapsido, the first oral Bruton’s tyrosine kinase inhibitor approved in the UK for adults with chronic spontaneous urticaria inadequately controlled by H1 antihistamines.
Remibrutinib | 10/08/2026 | By News Bureau
Novartis Wins Health Canada Approval for RHAPSIDO in CSU
Novartis has received Health Canada approval for RHAPSIDO (remibrutinib), a new oral treatment for adults with Chronic Spontaneous Urticari (CSU).
Remibrutinib | 29/07/2026 | By News Bureau | 147
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy